{"title":"健康受試者的"艱難抉擇"","authors":"嘉琪 王, 蕊 鄧","doi":"10.24112/ijccpm.212657","DOIUrl":null,"url":null,"abstract":"LANGUAGE NOTE | Document text in Chinese; abstract also in English.
 以新冠疫苗I期試驗的健康受試者為研究對象,基於深度訪談和虛擬民族志研究方法,採用NVivo11軟體進行編碼分析,發現健康受試者的參與動機多為積極動機,在抉擇過程中曾面臨內外矛盾而深陷糾結與掙扎。文章歸納出新冠疫苗受試者抉擇過程不同階段的動機與行為特點,即:萌生想法——躍躍欲試的受試者;進退狐疑——踽踽獨行的受試者;備受煎熬——忐忑不安的受試者;解惑釋疑——篤定前行的受試者。旨在真實地還原健康受試者的抉擇過程,消除社會偏見,為健康受試者和I期試驗去除污名,提升公眾的認知,增强健康受試者的認同感和歸屬感。
 Taking the Phase I trial of the 2019-nCoV vaccine as a case study, this paper examines the motivational and psychological development and behavioral patterns of healthy volunteers who participate in different phases of clinical trials for vaccines. The findings of a series of in-depth interviews and virtual ethnographical studies show that participation in a clinical trial such as that for the 2019-nCoV vaccine is a difficult choice for volunteers, as it entails exposure not only to medical risks but also to social prejudice. The paper provides a detailed account of how the volunteers for the Phase I 2019-nCoV vaccine trials made their choice to participate and how they overcame various doubts and fears to serve as responsible research partners.","PeriodicalId":41284,"journal":{"name":"International Journal of Chinese & Comparative Philosophy of Medicine","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chinese & Comparative Philosophy of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24112/ijccpm.212657","RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HISTORY & PHILOSOPHY OF SCIENCE","Score":null,"Total":0}
引用次数: 0
Abstract
LANGUAGE NOTE | Document text in Chinese; abstract also in English.
以新冠疫苗I期試驗的健康受試者為研究對象,基於深度訪談和虛擬民族志研究方法,採用NVivo11軟體進行編碼分析,發現健康受試者的參與動機多為積極動機,在抉擇過程中曾面臨內外矛盾而深陷糾結與掙扎。文章歸納出新冠疫苗受試者抉擇過程不同階段的動機與行為特點,即:萌生想法——躍躍欲試的受試者;進退狐疑——踽踽獨行的受試者;備受煎熬——忐忑不安的受試者;解惑釋疑——篤定前行的受試者。旨在真實地還原健康受試者的抉擇過程,消除社會偏見,為健康受試者和I期試驗去除污名,提升公眾的認知,增强健康受試者的認同感和歸屬感。
Taking the Phase I trial of the 2019-nCoV vaccine as a case study, this paper examines the motivational and psychological development and behavioral patterns of healthy volunteers who participate in different phases of clinical trials for vaccines. The findings of a series of in-depth interviews and virtual ethnographical studies show that participation in a clinical trial such as that for the 2019-nCoV vaccine is a difficult choice for volunteers, as it entails exposure not only to medical risks but also to social prejudice. The paper provides a detailed account of how the volunteers for the Phase I 2019-nCoV vaccine trials made their choice to participate and how they overcame various doubts and fears to serve as responsible research partners.
LANGUAGE NOTE | Document text in Chinese; abstract also in English.
以新冠疫苗I期试验的健康受试者为研究对象,基于深度访谈和虚拟民族志研究方法,采用NVivo11软体进行编码分析,发现健康受试者的参与动机多为积极动机,在抉择过程中曾面临内外矛盾而深陷纠结与挣扎。文章归纳出新冠疫苗受试者抉择过程不同阶段的动机与行为特点,即:萌生想法——跃跃欲试的受试者;进退狐疑——踽踽独行的受试者;备受煎熬——忐忑不安的受试者;解惑释疑——笃定前行的受试者。旨在真实地还原健康受试者的抉择过程,消除社会偏见,为健康受试者和I期试验去除污名,提升公众的认知,增强健康受试者的认同感和归属感。
Taking the Phase I trial of the 2019-nCoV vaccine as a case study, this paper examines the motivational and psychological development and behavioral patterns of healthy volunteers who participate in different phases of clinical trials for vaccines. The findings of a series of in-depth interviews and virtual ethnographical studies show that participation in a clinical trial such as that for the 2019-nCoV vaccine is a difficult choice for volunteers, as it entails exposure not only to medical risks but also to social prejudice. The paper provides a detailed account of how the volunteers for the Phase I 2019-nCoV vaccine trials made their choice to participate and how they overcame various doubts and fears to serve as responsible research partners.